RxDoctor Payments Data

Tara Thompson, NP

Family · Henderson, NVNPI 1568161651

Payments from drug & device makers

$636in general payments, 2019–2025

Across 20 payments — averaging $31.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$146
  • Novo Nordisk$142
  • AstraZeneca$137
  • Medtronic$73
  • GSK$46
  • Exact Sciences$31
  • plus $62 from 3 others

What the payments were for

  • Food & beverage$636100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$636 in reported general payments places this provider in the 60th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$83,562
Medicare patients
197
Services billed
1,035

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin66$101,800
OzempicSemaglutide55$71,001
MounjaroTirzepatide49$64,330
EliquisApixaban29$47,321
TrulicityDulaglutide25$34,317
FarxigaDapagliflozin Propanediol20$20,110
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$14,857
Breo ElliptaFluticasone/Vilanterol22$9,748
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$8,334
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$6,910
Bupropion XlBupropion Hcl56$5,388
NexletolBempedoic Acid12$4,613
DayvigoLemborexant13$4,295
Atorvastatin Calcium504$4,109
Albuterol Sulfate HfaAlbuterol Sulfate161$3,269

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$146$98,64774 claims
Novo NordiskOzempic$142$71,00155 claims
PfizerEliquis$24$47,32129 claims
GSKTrelegy Ellipta, Breo Ellipta$46$24,60539 claims
AstraZenecaFarxiga, Symbicort$137$23,18831 claims
AbbVieSynthroid$15$1,15311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,501 family providers in Nevada.

Other family in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →